Published in Semin Oncol on April 01, 2010
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med (2014) 1.44
Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1. Front Oncol (2014) 0.82
Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy. Oncoimmunology (2016) 0.75
Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res (1996) 6.62
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol (2008) 5.21
Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res (1996) 4.98
Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology (2008) 4.73
Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys (1997) 4.55
Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther (2000) 4.33
Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol (2007) 3.86
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol (2009) 3.80
Experience with more than 500 minimally invasive hepatic procedures. Ann Surg (2008) 3.23
Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science (1991) 3.14
Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther (2000) 2.94
Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res (2009) 2.74
The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther (2008) 2.72
American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol (2009) 2.52
Oncolytic viruses in cancer therapy. Cancer Lett (2007) 2.45
Oncolytic viral therapies - the clinical experience. Oncogene (2005) 2.30
Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer Suppl (1978) 2.28
The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors. Proc Natl Acad Sci U S A (1996) 2.09
Physical state of the latent herpes simplex virus genome in a mouse model system: evidence suggesting an episomal state. Virology (1987) 2.05
Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A (2001) 1.99
HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther (2004) 1.91
The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther (2002) 1.73
Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res (2002) 1.72
Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J (1999) 1.64
An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res (2005) 1.63
Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther (2002) 1.51
Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol (2009) 1.50
Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst (2006) 1.47
Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer (1957) 1.43
Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther (2001) 1.37
Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther (2002) 1.36
Antiviral drugs. N Engl J Med (1999) 1.36
Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases. Hum Gene Ther (2002) 1.26
Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors. Cancer Res (2008) 1.24
Minimally invasive localization of oncolytic herpes simplex viral therapy of metastatic pleural cancer. Cancer Gene Ther (2006) 1.23
The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth. Surgery (1974) 1.22
Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus. Cancer (1952) 1.21
The replication-competent oncolytic herpes simplex mutant virus NV1066 is effective in the treatment of esophageal cancer. Surgery (2003) 1.17
Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV. Hepatology (2005) 1.17
Response of Chinese hamster ovary cells to anticancer drugs under aerobic and hypoxic conditions. Br J Cancer (1981) 1.13
Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide. Mol Ther (2008) 1.12
Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther (2006) 1.11
Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum Gene Ther (2001) 1.10
Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol (1983) 1.10
Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin Cancer Res (2006) 1.09
A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. Mol Ther (2008) 1.09
Oncolytic herpes simplex virus-1 mutant expressing green fluorescent protein can detect and treat peritoneal cancer. Hum Gene Ther (2004) 1.08
Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J Am Coll Surg (2001) 1.06
Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas. Surgery (2007) 1.06
An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J (2000) 1.06
An update on treatment advances for the first-line therapy of metastatic colorectal cancer. Cancer J (2007) 1.05
Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. Hum Gene Ther (2000) 1.04
Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma. Head Neck (2008) 1.03
Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther (2005) 1.03
Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control. Cancer Res (2006) 1.02
Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207). Hum Gene Ther (1999) 1.00
Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma. Cancer Res (1997) 0.99
E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum Gene Ther (2001) 0.98
The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer. Ann Oncol (1995) 0.98
Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer. Ann Surg (2001) 0.97
Role of intraoperative thermoablation combined with resection in the treatment of hepatic metastasis from colorectal cancer. Arch Surg (2007) 0.94
Cytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanisms. Cancer Gene Ther (2007) 0.94
Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers. Arch Immunol Ther Exp (Warsz) (2008) 0.93
Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res (2004) 0.93
Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy. J Gene Med (2007) 0.92
Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin. Cancer (2004) 0.87
Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen. Cancer Res (2004) 0.86
Oncolytic herpesvirus with secretable angiostatic proteins in the treatment of human lung cancer cells. Anticancer Res (2005) 0.86
Correlation between serum CEA level and metabolic volume as determined by FDG PET in postoperative patients with recurrent colorectal cancer. Ann Nucl Med (2005) 0.86
Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice. Cancer Gene Ther (2008) 0.85
Utilizing ras signaling pathway to direct selective replication of herpes simplex virus-1. PLoS One (2009) 0.85
Serial levels of CA 19-9 and CEA in colonic cancer. J Clin Oncol (1986) 0.84
Neoadjuvant interleukin-12 immunogene therapy protects against cancer recurrence after liver resection in an animal model. Ann Surg (2000) 0.83
Studies in Hodgkin's syndrome; the association of viral hepatitis and Hodgkin's disease; a preliminary report. Cancer Res (1949) 0.83
Utilizing tumor hypoxia to enhance oncolytic viral therapy in colorectal metastases. Ann Surg (2004) 0.83
Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer. Curr Cancer Drug Targets (2007) 0.82
Oncolytic viral therapy for human ovarian cancer using a novel replication-competent herpes simplex virus type I mutant in a mouse model. Gynecol Oncol (2003) 0.82
Carcinoembryonic antigen directed herpes viral oncolysis improves selectivity and activity in colorectal cancer. Surgery (2004) 0.80
Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus. Cancer Lett (2009) 0.80
Antitumor activity of a selectively replication competent herpes simplex virus (HSV) with enzyme prodrug therapy. Anticancer Res (2009) 0.79
Chemotherapy of Metastatic Colorectal Cancer. Curr Treat Options Gastroenterol (2005) 0.78
Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg (2002) 8.30
The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33
Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol (2007) 4.95
Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire. J Clin Oncol (2002) 4.16
Pasireotide for postoperative pancreatic fistula. N Engl J Med (2014) 3.84
A selective approach to the resection of cystic lesions of the pancreas: results from 539 consecutive patients. Ann Surg (2006) 3.34
Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg (2008) 3.16
Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann Surg (2003) 3.14
Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer (2003) 2.96
Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol (2006) 2.66
American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol (2009) 2.52
Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol (2010) 2.51
Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma. Cancer Biol Ther (2006) 2.45
Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg (2003) 2.36
Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. J Clin Oncol (2003) 2.36
Operative drainage following pancreatic resection: analysis of 1122 patients resected over 5 years at a single institution. Ann Surg (2013) 2.29
Analysis of the extent of resection for adenocarcinoma of the gallbladder. Ann Surg Oncol (2008) 2.28
Predicting the risk of perioperative transfusion for patients undergoing elective hepatectomy. Ann Surg (2009) 2.27
The impact of margins on outcome after hepatic resection for colorectal metastasis. Ann Surg (2007) 2.23
Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg (2007) 2.22
The use of fresh frozen plasma after major hepatic resection for colorectal metastasis: is there a standard for transfusion? J Am Coll Surg (2003) 2.20
Combined blunt-clamp dissection and LigaSure ligation for hepatic parenchyma dissection: postcoagulation technique. J Am Coll Surg (2009) 2.19
Diagnosis, management, and outcomes of 115 patients with hepatic hemangioma. J Am Coll Surg (2003) 2.09
Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J Am Coll Surg (2003) 2.06
Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg (2003) 2.05
(124)I-huA33 antibody PET of colorectal cancer. J Nucl Med (2011) 2.01
Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg (2010) 1.98
Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg (2003) 1.97
Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. Ann Surg (2009) 1.94
Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas? Hepatology (2012) 1.94
Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg (2007) 1.86
Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg (2008) 1.85
Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer (2002) 1.85
Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. J Clin Oncol (2010) 1.80
Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg (2003) 1.79
A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. Ann Surg (2008) 1.76
Staging laparoscopy in patients with extrahepatic biliary carcinoma. Analysis of 100 patients. Ann Surg (2002) 1.75
Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann Surg Oncol (2011) 1.75
Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol (2005) 1.73
Ablation of perivascular hepatic malignant tumors with irreversible electroporation. J Am Coll Surg (2012) 1.71
Nectin-1 expression by squamous cell carcinoma is a predictor of herpes oncolytic sensitivity. Mol Ther (2007) 1.71
Laparoscopic adrenalectomy for isolated adrenal metastasis. Ann Surg Oncol (2007) 1.71
Overexpression of E2F-1 in lung and liver metastases of human colon cancer is associated with gene amplification. Cancer Biol Ther (2004) 1.67
Hepatocellular carcinoma: current surgical management. Gastroenterology (2004) 1.66
Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer (2006) 1.66
Management of primary liver sarcomas. Cancer (2007) 1.65
Caudate hepatectomy for cancer: a single institution experience with 150 patients. J Am Coll Surg (2005) 1.64
Yttrium 90 microsphere selective internal radiation treatment of hepatic colorectal metastases. Arch Surg (2007) 1.63
Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? Oncology (2011) 1.61
Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol (2006) 1.60
Partial hepatectomy for metastases from noncolorectal, nonneuroendocrine carcinoma. Ann Surg (2005) 1.60
Contemporary experience with postpancreatectomy hemorrhage: results of 1,122 patients resected between 2006 and 2011. J Am Coll Surg (2012) 1.58
Long-term outcomes following tumor ablation for treatment of bilateral colorectal liver metastases. JAMA Surg (2013) 1.58
Major hepatectomy with simultaneous pancreatectomy for advanced hepatobiliary cancer. J Am Coll Surg (2004) 1.58
Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Ann Surg (2011) 1.57
Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus. Surgery (2007) 1.54
Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68. Mol Cancer Ther (2009) 1.54
Gene therapy for rare diseases: summary of a National Institutes of Health workshop, September 13, 2012. Hum Gene Ther (2013) 1.54
Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma. Hum Gene Ther (2008) 1.53
Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg (2007) 1.52
Simple measurement of intra-abdominal fat for abdominal surgery outcome prediction. Arch Surg (2010) 1.52
18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg (2007) 1.51
Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery (2008) 1.50
Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol (2009) 1.50
Current management of pyogenic liver abscess: surgery is now second-line treatment. J Am Coll Surg (2010) 1.49
Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg (2005) 1.49
Perihepatic lymph node micrometastases impact outcome after partial hepatectomy for colorectal metastases. Ann Surg Oncol (2008) 1.48
Preoperative predictors for complications after pancreaticoduodenectomy: impact of BMI and body fat distribution. J Gastrointest Surg (2007) 1.47
Laparoscopic distal pancreatectomy: evolution of a technique at a single institution. J Am Coll Surg (2010) 1.46
Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma. Ann Surg (2010) 1.43
Changes in the management of benign liver tumours: an analysis of 285 patients. HPB (Oxford) (2012) 1.42
Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg (2002) 1.42
Safety and efficacy of preoperative portal vein embolization with polyvinyl alcohol in 58 patients with liver metastases. AJR Am J Roentgenol (2005) 1.42
Cystic lesions of the pancreas: changes in the presentation and management of 1,424 patients at a single institution over a 15-year time period. J Am Coll Surg (2011) 1.41
Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther (2006) 1.39
Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg (2007) 1.39
Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer. Ann Surg (2008) 1.39
Paracrine regulation of pancreatic cancer cell invasion by peripheral nerves. J Natl Cancer Inst (2010) 1.36
Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther (2002) 1.36
Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo. J Clin Endocrinol Metab (2008) 1.35
Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg (2003) 1.35
Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol (2008) 1.33
Solid pseudopapillary tumors of the pancreas. Clinical features, surgical outcomes, and long-term survival in 45 consecutive patients from a single center. J Gastrointest Surg (2010) 1.33
Gallbladder cancer: differences in presentation, surgical treatment, and survival in patients treated at centers in three countries. J Am Coll Surg (2010) 1.31
Fate of the remnant pancreas after resection of noninvasive intraductal papillary mucinous neoplasm. J Am Coll Surg (2007) 1.30
Current utility of staging laparoscopy for pancreatic and peripancreatic neoplasms. J Am Coll Surg (2007) 1.29
Local surgical, ablative, and radiation treatment of metastases. CA Cancer J Clin (2009) 1.28
Effect on outcome of recurrence patterns after hepatectomy for colorectal metastases. Ann Surg Oncol (2010) 1.27
Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases. Hum Gene Ther (2002) 1.26
Outcome of partial hepatectomy for large (> 10 cm) hepatocellular carcinoma. Cancer (2005) 1.26
Accurate staging for gallbladder cancer: implications for surgical therapy and pathological assessment. Ann Surg (2011) 1.24
Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases. Ann Surg Oncol (2012) 1.24
Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207). FASEB J (2004) 1.24
Polypoid lesions of the gallbladder: diagnosis and followup. J Am Coll Surg (2009) 1.24
Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses. J Gene Med (2006) 1.23
Laparoscopic versus open liver resection: a matched-pair case control study. J Gastrointest Surg (2009) 1.23
The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients. J Am Coll Surg (2012) 1.23
Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus. J Transl Med (2011) 1.22